IgG2

After pharmacogenetic analysis in a Phase II melanoma study for tremelimumab failed to yield any clinically meaningful gene-response markers, Pfizer inked a codevelopment deal with Debiopharm handing over Phase III development of the drug with a protein marker linked to response. But commercialization rights still belong to Pfizer.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.